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Background: Sino-nasal aspergillosis is a common nasal disease in dogs. Recommended treat-
ment protocols typically involve trephination of the frontal sinuses or the use of an antifungal
solution instilled into the frontal sinus under anesthesia, both of which have associated morbid-
ity and complications.
Objectives: To assess a minimally-invasive topical treatment protocol for sino-nasal aspergillosis
in dogs.
Animals: Twelve client-owned dogs diagnosed with sino-nasal aspergillosis that completed
recommended treatment.
Methods:Medical records were retrospectively reviewed to identify dogs with sino-nasal asper-
gillosis that received treatment. Fungal plaques were manually debrided and irrigated via frontal
sinuscopy in 12 dogs that then were treated topically with 1% topical clotrimazole cream. Irriga-
tion and topical medication application was achieved using a catheter placed retrograde directly
into the frontal sinuses using the Seldinger technique over a guidewire, thereby avoiding the
need for frontal sinus trephination. Invasion into the calvarium was recorded before treatment
but was not considered a criterion for exclusion. Debridement and cream deposition was
repeated every 2 weeks as needed until negative culture and histopathologic findings were
obtained.
Results: All dogs were cured (negative results for Aspergillus on endoscopy, fungal culture, and
histopathology) with a median of 2 treatments. Treatments were well tolerated, with minimal
adverse effects reported. Three dogs had evidence of erosion into the calvarium on computed
tomography imaging.
Conclusions and Clinical Importance: This protocol appears to be an effective and well-
tolerated minimally invasive treatment for sino-nasal aspergillosis, including in dogs with erosion
into the calvarium. Only mild adverse effects were noted.
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1 | INTRODUCTION
Sino-nasal aspergillosis accounts for 12%-34% of nasal disease in
dogs.1 Clinical signs include chronic facial pain, mucopurulent to
severe hemorrhagic nasal discharge, nasal planum depigmentation,
lethargy, and poor appetite.2 Because of high failure rates and adverse
effects of hepatotoxicity with PO therapy, topical treatment is the
standard of care for treatment. Clinical remission rates of 85%-94%
are reported using a variety of techniques including trephination of
the frontal sinus, direct sinuscopy, use of antifungal solutions with
prolonged (≥1 hour) contact time, and depot treatment using a cream
formulation.3–7 When rhinoscopy, fungal culture, or both rather than
clinical signs were used to define treatment success, remission and
cure rates were lower than previously described.8
Although sinus trephination can be well tolerated, up to 20% of
dogs experience adverse effects including discomfort, incision site
infections, SC emphysema and leakage of antifungal medication under
the skin, abscess formation, and penetration of skull resulting in
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antifungal drug leakage around the brain and in the retro-bulbar
space.2,3,5,9,10 Direct frontal sinuscopy allows for direct visualization
and manual debridement of fungal plaques, which results in higher
cure rates after a single treatment.11 Direct debridement using frontal
sinuscopy combined with depot treatment previously has been
described in 8 of 43 dogs.5 In the remaining 35 dogs with computed
tomography (CT) evidence of frontal sinus involvement, trephination
was performed. Although the overall success rate in the study was
94%, the outcome of the 8 dogs with frontal sinus involvement that
did not receive trephination was not specifically reported.
The combination of frontal sinuscopy with depot treatment com-
bines the least invasive approach with the efficacy and decreased
anesthesia time associated with depot treatment. Our objective was
to evaluate the success rate, as determined by negative culture and
histopathology, of topical treatment including direct visualization and
debridement of the frontal sinus using sinuscopy and subsequent
deposition of clotrimazole cream into the frontal sinus.
2 | MATERIALS AND METHODS
Sixteen dogs with sino-nasal aspergillosis that presented from
December 2013 to June 2016 were retrospectively identified. Diag-
nostic criteria included evidence of a destructive rhinitis on CT imag-
ing combined with at least 1 of the following: positive fungal culture,
characteristic fungi identified on histopathology, and fungal plaques
identified rhinoscopically. A fungal culture was considered positive
based on colony and cellular morphology. Dogs were excluded if med-
ical records were incomplete, if they were not given topical treatment
using guidewire-assisted endoscopically-placed catheters, if they did
not complete the full treatment, or if they had had a concurrent sinus
or nasal neoplasm or foreign body. Four dogs were excluded, 1
for which treatment was declined, 1 that had clotrimazole placed
directly into the nasal cavity rather than the frontal sinus, and 2 that
received a single treatment. Of the latter 2 dogs, 1 was lost to follow-
up after the first treatment and 1 was euthanized after the first
treatment because the owners did not want to continue with topical
treatment.
All 12 remaining dogs had routine hematology, serum biochemis-
try, a coagulation profile (prothrombin time, activated partial thrombo-
plastin time, and fibrinogen assay), and buccal mucosal bleeding time
performed before the first treatment. The dogs were anesthetized
routinely and a CT scan (Siemens SOMATOM Definition AS, Siemens
AG, Munich, Germany) was performed. A 6.5 mm (with 5 mm tip) flex-
ible endoscope (Lucera GIF-XP260, Olympus, Center Valley, Pennsyl-
vania) was used for both retrograde nasopharyngoscopy and
anterograde rhinoscopy and sinuscopy. Biopsy specimens of an appar-
ent fungal plaque or nearby region were collected for fungal culture
and histopathology. If fungal plaques were identified (Figure 1), treat-
ment for aspergillosis was performed.
The head was placed with the nose tilted down and the pharynx
was packed with 2-4 absorbent sponges (Metro-pak dental sponges,
Roots Vet Dental supplies, Hinckley, United Kingdom). Fungal plaques
in the frontal sinus and nasal cavity were fragmented and loosened
using biopsy forceps through the endoscope (Figure 1A). A 0.035 in
Basset (Straight Bentson guidewire, Infiniti Medical, Redwood City,
California; straight Bentson) wire was introduced into the sinus via
the endoscope biopsy channel (Figure 1B), and the scope was
removed over the guidewire, leaving the guidewire in place. An 8F or
10F rigid canine urinary catheter (Portex Dog Catheter with female
luer mount, Smiths Medical International, Hythe, Kent, United King-
dom) was trimmed so that the length approximated the distance from
the nares to the frontal sinus plus an additional 2-3 cm. The catheter
was passed over the wire into the frontal sinus; correct placement
was confirmed endoscopically (Figure 1C). The frontal sinus then was
irrigated vigorously through the catheter with 0.9% saline using a
60 mL syringe. Sinuscopic examination was performed alongside the
catheter after irrigating with approximately 200-300 mL of saline. This
process was repeated until no or minimal fungal plaques were
detected endoscopically (Figure 2A). One-percent clotrimazole cream
(Canesten 1% cream, Bayer, Hanover, New Jersey) warmed to body
temperature (to ease passage through the catheter) was instilled via
the catheter into the frontal sinus and nasal cavity (typically 50-70 g)
until cream was seen to exit the external nares (Figure 2B). This proce-
dure was repeated on both nasal cavities if the contralateral sinus was
affected. If the contralateral frontal sinus was normal on CT scan and
could not be accessed with the endoscope, the catheter was placed in
the caudal nasal cavity under endoscope visualization and the cream
instilled into the nasal cavity. The external nares were packed with
large cotton swabs and the dog was placed in dorsal recumbency for
10 minutes to allow distribution of the cream to the dorsal wall of the
frontal sinus. The patient was recovered with the nose tilted down
and monitored closely to minimize the risk of aspiration. Analgesia
(meloxicam 0.1 mg/kg [Metacam, Boehringer Ingelheim, St. Joseph,
Missouri] PO q24hr) was given for 5 days after the procedure. Antibi-
otics were not given to any of the dogs.
This treatment regimen was repeated at 2-week intervals until
there was no gross evidence of disease (Figure 2C). At this point, biop-
sies were repeated for histopathology and culture. The frontal sinus
was not debrided or flushed, and clotrimazole cream was deposited
through a catheter as previously described. Resolution of disease
(cure) was defined as the absence of fungal plaques on repeat sinu-
scopy, negative fungal culture, and no fungal elements seen on
histopathology.
3 | RESULTS
A total of 12 dogs were included. Breeds included Golden Retriever
(n = 4), Border Collie (n = 3), Collie cross, Cockapoo, Dalmatian cross,
Labrador Retriever, and Welsh Springer Spaniel. There were 9 males
(1 intact) and 3 females (1 intact). Age at the time of diagnosis ranged
from 1 to 13.5 years (mean, 6.7 years). Body weight ranged from 12.6
to 41.9 kg (median, 26.8 kg).
The median duration of clinical signs at presentation was
12 weeks, ranging from 3 to 48 weeks. Previous treatments before
referral included antibiotics (12/12), itraconazole (2/12), meloxicam
(4/12), corticosteroids (4/12), and chemotherapy (1/12, cyclophos-
phamide, doxorubicin, vincristine, and prednisolone protocol initiated
because the biopsy specimen initially was misdiagnosed as nasal
2
lymphoma). At the time of referral, the owners reported minimal or no
response to the aforementioned treatments.
Dogs presented with the following clinical signs: nasal discharge
(12/12, 7 unilateral and 5 bilateral), sneezing, reverse sneezing, or
both (12/12), epistaxis (10/12), facial pain (4/12), and lethargy (3/12).
Clinical examination disclosed submandibular lymph node enlarge-
ment (10/12), nasal depigmentation (5/12), mildly increased tempera-
ture (2/12), and nasal asymmetry (1/12).
Routine hematology, serum biochemistry, and coagulation profiles
were normal in 11/12 dogs. Mild neutrophilia was recorded in 1 dog.
The CT findings showed turbinate destruction, characteristic of
sino-nasal aspergillosis, in all dogs as previously described.12 Nasal
turbinate destruction was unilateral in 5 dogs and bilateral in 7 dogs.
Evidence of frontal sinus involvement (based on CT and sinuscopy)
was established in 10/12 dogs. Of these 10 dogs, 7 had unilateral
involvement. Three of these dogs had follow-up CT scans with no
evidence of contralateral involvement and none of them developed
clinical signs on the contralateral side. Three dogs had osteolytic
changes within the left internal frontal bone with visible communica-
tion between the frontal sinus and the frontal lobe of the brain (defect
size: 2 mm, 3.2 mm, and 9 mm). The dog with the 9 mm defect had
meningeal enhancement (Figure 3). The dog with the 2 mm defect also
had a cribriform plate defect of 4 mm.
In 11/12 dogs, fungal plaques were seen on rhinoscopy or sinu-
scopy: 2 on rhinscopy only, 8 on sinuscopy only, and 1 on both
rhinoscopy and sinuscopy. In 11/12 dogs, fungal culture was positive
for Aspergillus spp. In 8 dogs, characteristic fungi were seen on histo-
pathology. Seven of 12 dogs were positive on culture and histopathol-
ogy, with fungal plaques seen. In 3 dogs, culture and endoscopy were
positive for Aspergillus spp., but histopathology was negative. One dog
was diagnosed based on the presence of obvious fungal plaques alone
(no culture or biopsy was performed). One dog was diagnosed based
on positive culture and histopathology and characteristic CT changes
without obvious fungal plaques.
Clinical signs improved or resolved after first treatment in 10/12
dogs. Nasal discharge resolved in 3/12, improved in 7/12, and
remained unchanged in 2/12 Sneezing resolved in 8/12, improved in
2/12 and remained unchanged in 2/12. All dogs with epistaxis as a
presenting clinical sign (10 dogs) had resolution of epistaxis after a sin-
gle treatment. Facial pain resolved in 1/4 dogs after a single
treatment.
All 12 dogs completed a full therapeutic course until resolution of
disease was confirmed. Clinical remission was achieved after 1 treat-
ment in 2/12, 2 treatments in 5/12, 3 treatments in 3/12, and 4 treat-
ments in 2/12. The median number of treatments for remission was 2.
In the 3 dogs with bilateral frontal sinus involvement, 4 treatments
were required in 1 dog and 3 treatments in 2 dogs. The 2 dogs cured
after a single treatment had minimal serous nasal discharge as the
only persistent clinical sign, which resolved after the second (final)
instillation of clotrimazole at the time cure was confirmed. In 11 dogs,
FIGURE 1 Frontal sinuscopy demonstrating fungal plaques and placement of flushing and treatment catheter. (A) Plaques are being fragmented
and loosened using a biopsy forceps. (B) A 0.035 in Basset (straight Bentson) wire is placed into the frontal sinus through the biopsy channel of
the flexible endoscope. The scope is then withdrawn over the guidewire, leaving the guidewire in place. (C) A rigid canine urinary catheter is
trimmed to the appropriate length and inserted over the wire into the frontal sinus. The guidewire is then removed and the frontal sinus is flushed
vigorously with 0.9% NaCl solution.
FIGURE 2 Frontal sinuscopy after debridement with instillation and follow-up endoscopy. (A) At the completion of manual debridement and
flushing, the majority of fungal plaques have been flushed out. (B) Clotrimazole cream is instilled via the catheter into the frontal sinus. The sinus
is filled until cream is observed to protrude out of the sinus. The flexible endoscope is gradually withdrawn as cream is continuously instilled,
filling the nasal cavity. (C) After a single treatment in 1 dog, no fungal plaques are apparent in the frontal sinus. One final clotrimazole treatment is
performed as previously described.
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histopathology and fungal culture were negative once no gross
plaques were visualized. One dog was culture positive without gross
evidence of fungal plaques or clinical signs typical for aspergillosis.
One dog received an additional treatment beyond clinical remission
because of clinician preference, for a total of 3 treatments. Time
under anesthesia ranged from 75 to 115 minutes (median, 95 minutes)
for the first treatment with a repeat treatment, range of 20 to
60 minutes (median, 35 minutes). Frontal sinuscopy of the affected
sinus was possible in all 12 dogs and of the contralateral unaffected
sinus in 2 dogs as a result of the nasal turbinate destruction. Adverse
effects of treatment including a bloody or creamy nasal discharge for
up to 1 week after treatment (typically 3-5 days with blood stopping
by Day 3) and 2 dogs had an increase in reverse sneezing until cure.
No serious adverse events were noted. At the time of remission, epi-
staxis and pain resolved in all dogs, minimal serous nasal discharge
remained in 4/12 of the dogs and occasional sneezing was reported in
3/12 dogs.
The 3 dogs with potential central nervous system (CNS) involve-
ment were treated with the same protocol and received 4 to 5 treat-
ments (median, 4 treatments). Two of these dogs with potential CNS
involvement also were given itraconazole (Sporanox, Janssen,
Horsham, New Jersey) 5 mg/kg PO q24hr until resolution. All 3 dogs
appeared endoscopically to have intact epithelium over the area
where osteolysis was noted on CT scan, which increased clinician
confidence to treat. In a dog with marked frontal bone osteolysis, a
large piece of necrotic bone embedded into mucosa was removed by
gentle traction from the floor of the sinus during the fourth treatment.
Topical treatment was not performed during this treatment because
of concerns about possible defects in the epithelium over the osteoly-
tic area after removal of the necrotic bone fragment. Fungal culture
was negative at this stage, and no additional treatments were
performed.
Sino-nasal aspergillosis recurred in 2 dogs. One dog had recur-
rence 2 months after completing the initial course of treatment
(2 treatments) and received an additional 4 treatments for resolution
of disease. This dog was in clinical remission for the 22 months avail-
able for follow-up. The other dog had recurrence 7 months after com-
pletion of the initial course of treatment (2 treatments). This dog was
diagnosed with hyperadrenocorticism and a soft tissue sarcoma at the
time of recurrence. The owner declined repeat topical treatment and
PO itraconazole was prescribed. The remaining 10 dogs remained in
remission until death from unrelated causes or until they were lost to
follow-up. One dog was euthanized 2 months after remission because
of a bladder tumor, and 1 died 13 months after remission of an unre-
lated cause. The remaining 8/12 remained in clinical remission during
the follow-up period, that ranged from 4 to 33 months (median, 11.5).
4 | DISCUSSION
This minimally-invasive approach to treatment of sino-nasal aspergil-
losis was effective in resolving Aspergillus in all treated dogs with mini-
mal morbidity, with a second course of treatment required in 2/12
dogs. All dogs completing the recommended topical treatment proto-
col were cured until the time of euthanasia (unrelated to sino-nasal
aspergillosis) or were lost to follow-up. This finding compares favor-
ably with previous reported remission rates up to 94%.5 Our treat-
ment protocol incorporated confirmation of cure by frontal sinuscopy
combined with negative culture and histopathology. Previous studies
based success rates largely on clinical remission and therefore may over-
estimate the efficacy of treatment. Clinical signs are not necessarily indic-
ative of disease status. Repeat biopsy and culture are required to confirm
resolution, as evidenced by the 1 dog in our study that was positive on
culture with no clinical signs and no gross evidence of disease.
The diagnosis of aspergillosis was based on a combination of evi-
dence of gross disease, positive fungal culture, and positive histopath-
ologic findings. One of the 12 dogs was diagnosed based on the
presence of gross disease along with characteristic changes on the CT
scan. As a retrospective study, culture and histopathology results
were not available for all dogs. At the time of initial diagnosis, culture
and histopathology were performed in 11/12 dogs; 1 dog was diag-
nosed based on the presence of fungal plaques and compatible CT
changes. Three dogs were negative on histopathology despite having
a positive fungal culture. The reason for this discrepancy is unclear,
and attempts had been made to collect biopsy specimens near the pla-
que whenever possible. It is possible that culture is a more sensitive
modality than biopsy for diagnosis of aspergillosis, although such a
conclusion is beyond the scope of our study. In 11/12 dogs, cure was
confirmed by negative culture and histopathology. For the remaining
1 dog, cure was presumed because no fungal plaques were seen endo-
scopically and clinical signs had resolved.
Our treatment failure rate of 17%, is similar to previously
reported rates of 11%-20%.8,13,14 One of the 2 dogs was diagnosed
with hyperadrenocorticism which may have predisposed to
recurrence.
FIGURE 3 Frontal bone defect. Computed tomography image
demonstrating osteolytic changes within the left internal frontal bone
with visible communication between the frontal sinus and the frontal
lobe of the brain.
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Previous studies that have used endoscopically-placed catheters
have used a method that involves the biopsy forceps protruding from
the endoscope and grasping a suture that is attached to the cathe-
ter.5,6,14,15 Although that technique is similarly minimally invasive, the
forceps may induce trauma while being passed into the frontal sinus.
Also, because both the endoscope and the catheter must simulta-
neously pass through the naso-frontal ostium, it may not be possible
in some dogs in which the ostium is not large enough. We were able
to successfully access and treat the affected frontal sinus in all dogs
endoscopically, even where the ostium was narrow.
Three dogs with potential CNS involvement (based on CT scan
results) and with intact mucosal epithelium covering the defect were
treated using the same protocol (in addition to PO itraconazole in
2 dogs) for a total of 13 treatments, with no complications. This
included 1 dog with a fairly large 9 mm defect and secondary menin-
geal enhancement. The remaining defects were small to moderate
(up to 4 mm). Previous reports describe a total of 10 dogs with CNS
involvement treated with topical antifungal medication with no com-
plications.5,8,12 Although our treatment protocol appears to be safe
for dogs with frontal bone or cribriform plate destruction, further
assessment with increased numbers of patients would be required to
definitively determine safety.
In unilateral disease where there was no destruction on the con-
tralateral side, it was not possible in most dogs to perform frontal
sinuscopy on the apparently unaffected side. CT scans showed no evi-
dence of disease and in those dogs that had follow-up CT scans; no
disease process became evident in the unaffected sinuses and no dog
developed clinical signs on the contralateral side.
In summary, minimally-invasive debridement and depot treatment
appears to be an effective and well-tolerated technique for the treat-
ment of sino-nasal aspergillosis in dogs, with minimal morbidity and a
cure rate of up to 100%.
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